The University of Tokyo | Japan
Dr. Hideyuki Takizawa is Chief Medical Officer and Chief Research Officer at Cliffhanger Inc., where he also leads the Division of Clinical Operations and Clinical Research Development (CROs and pharmaceutical companies) in Tokyo. He earned his MD and MSc from the Graduate School of Medicine at The University of Tokyo, followed by a PhD in Internal Medicine, awarded with honours for scientific research excellence and a translational medicine award. His doctoral work spanned clinical laboratory medicine and internal medicine, and focused on the biochemical and clinical mechanisms that link lipid metabolism to metabolic and cardiovascular disease, especially diabetes mellitus. Dr. Takizawa’s research has centred on serum sphingolipids and glycerophospholipids—specifically lipid subclasses such as phosphatidylinositol/lysophosphatidylinositol, phosphatidylglycerol/lysophosphatidylglycerol, and ceramides—and their associations with diabetes and its vascular and metabolic complications. He has applied omics-based lipid profiling to integrate molecular, cellular and clinical observations, thereby advancing translational medicine and precision treatment strategies for metabolic disorders.
Profile: Orcid
Featured Publications
Takizawa, H., Uranbileg, B., Yutaka, Y., & Kurano, M. (2025). Serum sphingolipid and glycerophospholipid synthesis, especially phosphatidylinositol/lysophosphatidylinositol, phosphatidylglycerol/lysophosphatidylglycerol, and ceramides, are significantly influenced by diabetes mellitus and associated with its complications. Diabetology, 6(10), Article 112.